Duodenal-type follicular lymphoma

Last updated
Duodenal-type follicular lymphoma
Other namesDuodenal follicular lymphoma
Specialty Hematology, oncology

Duodenal-type follicular lymphoma (DFL) is a form of lymphoma in which certain lymphocyte types, the B-cell-derived centrocytes and centroblasts, form lymph node follicle-like structures principally in the duodenum and other parts of the small intestine. It is an indolent disease which on rare occasions progresses to a more aggressive lymphoma that spreads beyond these originally involved sites. [1]

Contents

The disorder now termed DFL had been considered to be a follicular lymphoma that develops in one or more sites of the GI tract (i.e. stomach, duodenum, jejunum, small intestine, large intestine and rectum) as well as in various sites outside of the GI tract; this contrasts with other forms of follicular lymphoma which do not involve the GI tract. [1] The disorder was regarded as a subtype of follicular lymphoma termed primary intestinal follicular lymphomas or Primary gastrointestinal tract follicular lymphomas. [2] However, follicular lymphomas of the duodenum and other parts of the small intestine differ from the other forms of primary intestinal lymphomas in that they are indolent, highly localizes disorders that have a low rate of progression to a systemic disease. In consequence, the World Health Organization (2017) kept the more widespread primary intestinal lymphomas within the follicular lymphoma category and reclassified duodenal-/small intestinal-localized lymphoma as a distinct disease entity, DFL. [3]

DFL, while currently considered a malignant disease, has many clinical features which are more similar to the benign predecessor of follicular lymphomas viz., in situ follicular lymphoma, than to follicular lymphoma. [4] Like in situ follicular lymphoma, DFL is most commonly a symptom-free disease that is diagnosed incidentally in patients who are undergoing endoscopy for other reasons. [2] Also like in situ follicular lymphoma, DFL may in rare cases regress spontaneously [4] or progress to a more serious and aggressive form. [5]

Presentation

DFL most commonly afflicts middle-aged adults with a male to female ration of ~1. The disease is usually asymptomatic and diagnosed as an unexpected finding when examining patients by upper GI tract endoscopy conducted for other reasons. [2] A minority of patients present vague abdominal symptoms [6] or, rarely, more specific and serious symptoms such as obstructive jaundice caused by tumors in the duodenum which occlude the bile duct. [7] The endoscopic examination typically reveals one or more polyps, nodules, or confluent whitish granules located in various parts of the GI tract [7] which in a study of 54 patients conducted in Japan were distributed as follows: first (i.e. superior or bulbus) part of the duodenum, 4 patients; second (i.e. descending) part of the duodenum, 54 patients; combined third (i.e. horizontal or inferior), and fourth (i.e. ascending) part of the duodenum, 31 patients; jejunum, 44 patients; ileum, 17 patients; cecum, 13 patients; colon and rectum, each 2 patients; and stomach and esophagus, no patients. Lesions were limited to the second part of the duodenum in only 7 patients. [1] In some cases, the lesions may be ulcerated. [6]

Pathophysiology

DFL is due to the accumulation of monoclonal (i.e. cells descendent from a single ancestral cell) centrocytes and their precursor centroblasts to form follicle-like structures in the duodenum and other parts of the small intestine. In virtually all cases of the disease, these cells bear a pathological genomic abnormality that is typical of most but not all forms of follicular lymphoma, i.e. a translocation between position 32 on the long (i.e. "q") arm of chromosome 14 and position 21 on chromosome 18's q arm. This t(14:18)q32:q21) translocation juxtaposes the B-cell lymphoma 2 (BCL2) gene on chromosome 18 at position q21.33 near to the immunoglobulin heavy chain locus (IGH@) on chromosome 14 at position q21, and in consequence causes the overexpression of this gene's product protein, BCL2 apoptosis regulator (i.e. Bcl2). Blc2 functions to inhibit programmed cell death thereby prolonging cell survival. [8] The overexpression of Bcl2 in the B-cells of ISFL is thought to be a critical factor in their pathological accumulation and subsequent malignant progression. [7] Gene expression profiling studies find that the tissues involved in DFP highly express certain genes that are unlike those expressed by the tissues in other forms of follicular lymphoma and more closely match those expressed by the tissues in MALT lymphoma, a lymphoma involving the mucosa-associated lymphoid tissue of the GI tract, airways, conjunctiva, vulvo-vagina tract, and skin. The highly express genes in both disorders include: 1) CCL20, a chemokine that is a chemoattractant for lymphocytes and 2) MAdCAM-1, a cell adhesion protein on mucosal vascular endothelial cells that binds to the α4β7 homing receptor on lymphocytes. [9] and 3) C-C chemokine receptor type 6, which is the lymphocyte receptor for CCL20. [7] Working together, these genomic abnormalities are thought to deliver virtually immortalized centrocytes and centroblasts to the involved GI tract tissues in duodenal-type follicular lymphoma. [1] Furthermore, The malignant cells in DFL express immunoglobulin heavy chains made from specific rather than various gene segments of the IGH@ region on chromosome 14. In one study, for example, heavy chains made form VH4 and VH5 segments were expressed in a higher percentage of DFL cases than expected. These findings, along with those showing similarities in the profiles of highly expressed genes in DFL and mantle cell lymphoma suggest that DFL, like mantle cell lymphoma, develops as a consequence of chronic inflammation and specific antigen stimulation. In support of this possibility, there have been reports that DFL regresses in patients who are successfully treated for concurrent Helicobacter pylori infestation of the GI tract. [6]

Diagnosis

Histological examination of the lesions in DFL usually reveals them to be localized to the GI tract mucosa and submucosa. [6] The lesions consist of abnormal germinal center-containing lymphoid follicles overcrowded with a uniformly-sized population of malignant centrocytes and rare centroblasts. [6] The lesions are classified as low grade (i.e. Lugano classification Grades 1 or 2) in 95-100% of cases. Immunochemical analyses indicate that the latter cells express CD20, CD10, BCL6, [2] and CD79A [6] and have a very low proliferation rate as defined by the intensity of their expression of Ki-67. [6] They also overexpress Bcl2 as a consequence of having the t(14:18)q32:q21) translocation. These findings are similar to those in follicular lymphoma but the malignant cells in DFL generally have fewer genomic abnormalities than those in follicular lymphoma and the profile of overexpressed genes in DFL tissues more closely resemble those in marginal zone than follicular lymphoma tissues. The diagnosis of DFL depends on finding: the cited histological, and immunochemical abnormalities; the t(14:18)q32:q21) translocation; and no evidence that the disease ranges outside of the GI tract as evidenced by negative results for, e.g. bone marrow biopsy and CT scan of the abdomen which thereby rule out involvement of the bone marrow and mesenteric as well as other abdominal lymph node, respectively. [2]

Differential diagnoses

Follicular lymphoma differs from DFL by having: lesions which commonly lie outside of the GI tract sites outlined in the Presentation section; [1] a histology more often categorized as Grade 3; and malignant cells that express activation-induced cytidine deaminase [6] but not CD27, [9] CCL20, MAdCAM-1, or C-C chemokine receptor type 6. [7]

MALT lymphoma differs from DFL by having: lesions which commonly lie in the stomach and other tissues outside of the GI tract sites outlined in the Presentation section [6] (except for a special subtype of malt lymphoma termed immunoproliferative small intestinal disease that is endemic to the Middle East [10] ); involvement of malignant B-cells that do not express CD5, CD10, or BCL6 and commonly have a translocation between chromosomes 18 and 11, i.e. t(11:18) but not the t(14:18)q32:q21) translocation; [6] and associations with chronic inflammatory diseases and chronic antigen stimulation; [6]

Mantle cell lymphoma differs from DFL by having: only occasional involvement of the GI tract with polyps that on histologic examination may involve the lamina propria and often infiltrate between rather that replacing intestinal glands and malignant cells which commonly express cyclin D1 and a translocation between chromosomes 11 and 14, i.e. t(11:14) but not the t(14:18)q32:q21). translocation. [6]

Treatment

DFL is generally an indolent disease which progresses to a more aggressive form in <10% of cases. [2] A watch-and-wait strategy has been a generally recommended treatment for the disease in the United States, [2] Japan, [9] and Europe. [7] However, numerous approaches have been used to treat the disease. Patients with disease that is contained within a limited radiation field have been treated with radiation therapy to attain overall 10 year survival rates of 60-80%. However, one study found that radiation-treated patients had a relapse rate of 48%. A retrospective analysis conducted on a small number (i.e. 63) of patients found complete regression rates for a watch-and-wait tactic, radiotherapy, and rituximab (a monoclonal antibody directed against CD20) of 29%, 100%, 80%, respectively. The complete regression rate for a CHOP chemotherapy regimen, CHOP plus rituximab regimen, radiotherapy plus rituximab regimen, pancreaticoduodenectomy (i.e. surgical removal of the duodenum and pancreas), and other chemotherapeutic regimens, when combined as a single group, was 64%. Only two patients in this study had diseases which progressed to outside of the GI tract; both were in the watch-and-wait group. Until further studies are conducted to define the optimal regimens for treating DFL, most patients with the disease are being initially treated with a watch-and-wait approach in order to avoid the toxic side-effects of the cited alternate regimens. [6]

Related Research Articles

<span class="mw-page-title-main">Tumors of the hematopoietic and lymphoid tissues</span> Tumors that affect the blood, bone marrow, lymph, and lymphatic system

Tumors of the hematopoietic and lymphoid tissues or tumours of the haematopoietic and lymphoid tissues are tumors that affect the blood, bone marrow, lymph, and lymphatic system. Because these tissues are all intimately connected through both the circulatory system and the immune system, a disease affecting one will often affect the others as well, making aplasia, myeloproliferation and lymphoproliferation closely related and often overlapping problems. While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions. Not all hematological disorders are malignant ("cancerous"); these other blood conditions may also be managed by a hematologist.

<span class="mw-page-title-main">Anaplastic large-cell lymphoma</span> Medical condition

Anaplastic large-cell lymphoma (ALCL) refers to a group of non-Hodgkin lymphomas in which aberrant T cells proliferate uncontrollably. Considered as a single entity, ALCL is the most common type of peripheral lymphoma and represents ~10% of all peripheral lymphomas in children. The incidence of ALCL is estimated to be 0.25 cases per 100,000 people in the United States of America. There are four distinct types of anaplastic large-cell lymphomas that on microscopic examination share certain key histopathological features and tumor marker proteins. However, the four types have very different clinical presentations, gene abnormalities, prognoses, and/or treatments.

<span class="mw-page-title-main">Follicular lymphoma</span> Cancer originating in lymph nodes

Follicular lymphoma (FL) is a cancer that involves certain types of white blood cells known as lymphocytes. The cancer originates from the uncontrolled division of specific types of B-cells known as centrocytes and centroblasts. These cells normally occupy the follicles in the germinal centers of lymphoid tissues such as lymph nodes. The cancerous cells in FL typically form follicular or follicle-like structures in the tissues they invade. These structures are usually the dominant histological feature of this cancer.

<span class="mw-page-title-main">MALT lymphoma</span> Medical condition

MALT lymphoma is a form of lymphoma involving the mucosa-associated lymphoid tissue (MALT), frequently of the stomach, but virtually any mucosal site can be affected. It is a cancer originating from B cells in the marginal zone of the MALT.

<span class="mw-page-title-main">Primary effusion lymphoma</span> Medical condition

Primary effusion lymphoma (PEL) is classified as a diffuse large B cell lymphoma. It is a rare malignancy of plasmablastic cells that occurs in individuals that are infected with the Kaposi's sarcoma-associated herpesvirus. Plasmablasts are immature plasma cells, i.e. lymphocytes of the B-cell type that have differentiated into plasmablasts but because of their malignant nature do not differentiate into mature plasma cells but rather proliferate excessively and thereby cause life-threatening disease. In PEL, the proliferating plasmablastoid cells commonly accumulate within body cavities to produce effusions, primarily in the pleural, pericardial, or peritoneal cavities, without forming a contiguous tumor mass. In rare cases of these cavitary forms of PEL, the effusions develop in joints, the epidural space surrounding the brain and spinal cord, and underneath the capsule which forms around breast implants. Less frequently, individuals present with extracavitary primary effusion lymphomas, i.e., solid tumor masses not accompanied by effusions. The extracavitary tumors may develop in lymph nodes, bone, bone marrow, the gastrointestinal tract, skin, spleen, liver, lungs, central nervous system, testes, paranasal sinuses, muscle, and, rarely, inside the vasculature and sinuses of lymph nodes. As their disease progresses, however, individuals with the classical effusion-form of PEL may develop extracavitary tumors and individuals with extracavitary PEL may develop cavitary effusions.

<span class="mw-page-title-main">Intravascular lymphomas</span> Medical condition

Intravascular lymphomas (IVL) are rare cancers in which malignant lymphocytes proliferate and accumulate within blood vessels. Almost all other types of lymphoma involve the proliferation and accumulation of malignant lymphocytes in lymph nodes, other parts of the lymphatic system, and various non-lymphatic organs but not in blood vessels.

<span class="mw-page-title-main">Diffuse large B-cell lymphoma</span> Type of blood cancer

Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies. It is the most common form of non-Hodgkin lymphoma among adults, with an annual incidence of 7–8 cases per 100,000 people per year in the US and UK. This cancer occurs primarily in older individuals, with a median age of diagnosis at ~70 years, although it can occur in young adults and, in rare cases, children. DLBCL can arise in virtually any part of the body and, depending on various factors, is often a very aggressive malignancy. The first sign of this illness is typically the observation of a rapidly growing mass or tissue infiltration that is sometimes associated with systemic B symptoms, e.g. fever, weight loss, and night sweats.

<span class="mw-page-title-main">Enteropathy-associated T-cell lymphoma</span> Complication of coeliac disease

Enteropathy-associated T-cell lymphoma (EATL), previously termed enteropathy-associated T-cell lymphoma, type I and at one time termed enteropathy-type T-cell lymphoma (ETTL), is a complication of coeliac disease in which a malignant T-cell lymphoma develops in areas of the small intestine affected by the disease's intense inflammation. While a relatively rare disease, it is the most common type of primary gastrointestinal T-cell lymphoma.

<span class="mw-page-title-main">Blastic plasmacytoid dendritic cell neoplasm</span> Medical condition

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of lymphocyte-derived cutaneous lymphoma and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma, and agranular CD4+ NK cell leukemia. Later, however, the disease was determined to be a malignancy of plasmacytoid dendritic cells rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the World Health Organization designated BPDCN to be in its own separate category within the myeloid class of neoplasms. It is estimated that BPDCN constitutes 0.44% of all hematological malignancies.

<span class="mw-page-title-main">Marginal zone lymphoma</span> Group of lymphomas

Marginal zone lymphomas, also known as marginal zone B-cell lymphomas (MZLs), are a heterogeneous group of lymphomas that derive from the malignant transformation of marginal zone B-cells. Marginal zone B cells are innate lymphoid cells that normally function by rapidly mounting IgM antibody immune responses to antigens such as those presented by infectious agents and damaged tissues. They are lymphocytes of the B-cell line that originate and mature in secondary lymphoid follicles and then move to the marginal zones of mucosa-associated lymphoid tissue (MALT), the spleen, or lymph nodes. Mucosa-associated lymphoid tissue is a diffuse system of small concentrations of lymphoid tissue found in various submucosal membrane sites of the body such as the gastrointestinal tract, mouth, nasal cavity, pharynx, thyroid gland, breast, lung, salivary glands, eye, skin and the human spleen.

Lennert lymphoma, also termed lymphoepithelioid lymphoma, lymphoepithelioid variant of peripheral T-cell lymphoma, and epithelioid cellular lymphogranulomatosis, is a rare subtype of the T cell lymphomas. It was first characterized by Karl Lennert in 1952 as a variant of Hodgkin lymphoma based on the presence of cells resembling the Reed–Sternberg cells that typify Hodgkin lymphoma. However, later studies concluded that these cells are not Reed-Sternberg cells and that Lennert lymphoma is not a variant of Hodgkin lymphoma.

<span class="mw-page-title-main">Extranodal NK/T-cell lymphoma, nasal type</span> Medical condition

Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) is a rare type of lymphoma that commonly involves midline areas of the nasal cavity, oral cavity, and/or pharynx At these sites, the disease often takes the form of massive, necrotic, and extremely disfiguring lesions. However, ENKTCL-NT can also involve the eye, larynx, lung, gastrointestinal tract, skin, and various other tissues. ENKTCL-NT mainly affects adults; it is relatively common in Asia and to lesser extents Mexico, Central America, and South America but is rare in Europe and North America. In Korea, ENKTCL-NT often involves the skin and is reported to be the most common form of cutaneous lymphoma after mycosis fungoides.

Epstein–Barr virus–associated lymphoproliferative diseases are a group of disorders in which one or more types of lymphoid cells, i.e. B cells, T cells, NK cells, and histiocytic-dendritic cells, are infected with the Epstein–Barr virus (EBV). This causes the infected cells to divide excessively, and is associated with the development of various non-cancerous, pre-cancerous, and cancerous lymphoproliferative disorders (LPDs). These LPDs include the well-known disorder occurring during the initial infection with the EBV, infectious mononucleosis, and the large number of subsequent disorders that may occur thereafter. The virus is usually involved in the development and/or progression of these LPDs although in some cases it may be an "innocent" bystander, i.e. present in, but not contributing to, the disease.

Natural killer cell enteropathy, also termed NK cell enteropathy (NKCE), and a closely related disorder, lymphomatoid gastropathy (LG), are non-malignant diseases in which one type of lymphocyte, the natural killer cell, proliferates excessively in the gastrointestinal tract. This proliferation causes red, sore-like spots, raised lesions, erosions, and ulcers in the mucosal layer surrounding the GI tract lumen. Both disorders cause either no or only vague symptoms of GI tract disturbances such as nausea, vomiting, and bleeding.

Indolent T cell lymphoproliferative disorder of the gastrointestinal tract or Indolent T cell lymphoproliferative disorder of the GI tract (ITCLD-GT) is a rare and recently recognized disorder in which mature T cell lymphocytes accumulation abnormally in the gastrointestinal tract. This accumulation causes various lesions in the mucosal layer lining the GI tract. Individuals with ITCLD-GT commonly complain of chronic GI tract symptoms such as nausea, vomiting, diarrhea, abdominal pain, and rectal bleeding.

Monomorphic epitheliotropic intestinal T cell lymphoma (MEITL) is an extremely rare peripheral T-cell lymphoma that involves the malignant proliferation of a type of lymphocyte, the T cell, in the gastrointestinal tract. Over time, these T cells commonly spread throughout the mucosal lining of a portion of the GI tract, lead to GI tract nodules and ulcerations, and cause symptoms such as abdominal pain, weight loss, diarrhea, obstruction, bleeding, and/or perforation.

In situ lymphoid neoplasia is a precancerous condition newly classified by the World Health Organization in 2016. The Organization recognized two subtypes of ISLN: in situ follicular neoplasia (ISFN) and in situ mantle cell neoplasia (ISMCL). ISFN and ISMCL are pathological accumulations of lymphocytes in the germinal centers and mantle zones, respectively, of the follicles that populate lymphoid organs such as lymph nodes. These lymphocytes are monoclonal B-cells that may develop into follicular (FL) and mantle cell (MCL) lymphomas, respectively.

Pediatric-type follicular lymphoma (PTFL) is a disease in which malignant B-cells accumulate in, overcrowd, and cause the expansion of the lymphoid follicles in, and thereby enlargement of the lymph nodes in the head and neck regions and, less commonly, groin and armpit regions. The disease accounts for 1.5% to 2% of all the lymphomas that occur in the pediatric age group.

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a malignancy of B cells. B-cells are lymphocytes that normally function in the humoral immunity component of the adaptive immune system by secreting antibodies that, for example, bind to and neutralize invasive pathogens. Among the various forms of B-cell lymphomas, THRLBCL is a rarely occurring subtype of the diffuse large B-cell lymphomas (DLBCL). DLBCL are a large group of lymphomas that account for ~25% of all non-Hodgkin lymphomas worldwide. THRLBCL is distinguished from the other DLBCL subtypes by the predominance of non-malignant T-cell lymphocytes and histiocytes over malignant B-cells in its tumors and tissue infiltrates.

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a cutaneous lymphoma skin disease that occurs mostly in elderly females. In this disease, B cells become malignant, accumulate in the dermis and subcutaneous tissue below the dermis to form red and violaceous skin nodules and tumors. These lesions typically occur on the lower extremities but in uncommon cases may develop on the skin at virtually any other site. In ~10% of cases, the disease presents with one or more skin lesions none of which are on the lower extremities; the disease in these cases is sometimes regarded as a variant of PCDLBL, LT termed primary cutaneous diffuse large B-cell lymphoma, other (PCDLBC-O). PCDLBCL, LT is a subtype of the diffuse large B-cell lymphomas (DLBCL) and has been thought of as a cutaneous counterpart to them. Like most variants and subtypes of the DLBCL, PCDLBCL, LT is an aggressive malignancy. It has a 5-year overall survival rate of 40–55%, although the PCDLBCL-O variant has a better prognosis than cases in which the legs are involved.

References

  1. 1 2 3 4 5 Takata K, Miyata-Takata T, Sato Y, Yoshino T (2014). "Pathology of follicular lymphoma". Journal of Clinical and Experimental Hematopathology. 54 (1): 3–9. doi: 10.3960/jslrt.54.3 . PMID   24942941.
  2. 1 2 3 4 5 6 7 Weindorf SC, Smith LB, Owens SR (November 2018). "Update on Gastrointestinal Lymphomas". Archives of Pathology & Laboratory Medicine. 142 (11): 1347–1351. doi: 10.5858/arpa.2018-0275-RA . PMID   30407861.
  3. ↑ Yoshino T, Takata K, Tanaka T, Sato Y, Tari A, Okada H (December 2018). "Recent progress in follicular lymphoma in Japan and characteristics of the duodenal type". Pathology International. 68 (12): 665–676. doi:10.1111/pin.12733. PMID   30456840. S2CID   53871784.
  4. 1 2 Xerri L, Dirnhofer S, Quintanilla-Martinez L, Sander B, Chan JK, Campo E, et al. (February 2016). "The heterogeneity of follicular lymphomas: from early development to transformation". Virchows Archiv. 468 (2): 127–39. doi:10.1007/s00428-015-1864-y. PMID   26481245. S2CID   2978889.
  5. ↑ Lynch RC, Gratzinger D, Advani RH (July 2017). "Clinical Impact of the 2016 Update to the WHO Lymphoma Classification". Current Treatment Options in Oncology. 18 (7): 45. doi:10.1007/s11864-017-0483-z. PMID   28670664. S2CID   4415738.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 Marks E, Shi Y (April 2018). "Duodenal-Type Follicular Lymphoma: A Clinicopathologic Review". Archives of Pathology & Laboratory Medicine. 142 (4): 542–547. doi: 10.5858/arpa.2016-0519-RS . PMID   29565210.
  7. 1 2 3 4 5 6 Foukas PG, de Leval L (January 2015). "Recent advances in intestinal lymphomas". Histopathology. 66 (1): 112–36. doi:10.1111/his.12596. PMID   25639480. S2CID   20669863.
  8. ↑ EntrezGene 596
  9. 1 2 3 Takata K, Miyata-Takata T, Sato Y, Iwamuro M, Okada H, Tari A, Yoshino T (January 2018). "Gastrointestinal follicular lymphoma: Current knowledge and future challenges". Pathology International. 68 (1): 1–6. doi:10.1111/pin.12621. PMID   29292593. S2CID   206275496.
  10. ↑ Thieblemont C, Zucca E (2017). "Clinical aspects and therapy of gastrointestinal MALT lymphoma". Best Practice & Research. Clinical Haematology. 30 (1–2): 109–117. doi:10.1016/j.beha.2017.01.002. PMID   28288705.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.